Androgen deprivation therapy in advanced prostate cancer: is intermittent therapy the new standard of care?
about
Maximal testosterone suppression in the management of recurrent and metastatic prostate cancerImproving intermittent androgen deprivation therapy: lessons learned from basic and translational researchNadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADTHormonal therapy in metastatic prostate cancer: current perspectives and controversiesEvaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details.Suppression of the Hypothalamic-pituitary-adrenal Axis by Maximum Androgen Blockade in a Patient with Prostate Cancer.Extracellular vesicles for personalized therapy decision support in advanced metastatic cancers and its potential impact for prostate cancer.Loss of SUMOylation on ATF3 inhibits proliferation of prostate cancer cells by modulating CCND1/2 activity.Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer.Association of SLCO2B1 Genotypes With Time to Progression and Overall Survival in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer.Integrative transcriptome analysis identifies genes and pathways associated with enzalutamide resistance of prostate cancer.Reporting and ideal testosterone levels in men undergoing androgen deprivation for prostate cancer-time for a rethink?
P2860
Q29994552-7268889E-3EB4-4185-B96B-9135C0446D7DQ33922371-FB9B2D11-01CA-4756-B052-5AAC7D0A6C58Q35215038-D607F6CD-CA9B-450F-AAA9-E96062CBDF22Q35569303-65852CBB-0146-4BD7-8D2A-5A98E0669CB6Q37592301-75C13443-E77C-4D16-A5E9-F930AAEC9E1DQ37616833-FB4B7648-BD0C-4647-ABF7-AC2927CECD05Q38600919-19464D4E-5AE4-49FC-950E-296436EBD41AQ39165172-DE67FDB2-ECEF-44C8-9076-BA8EA8D407F0Q40395168-04E5270F-3490-4CED-A02A-613FDFAE980AQ42019892-A081C5AC-5EFC-4D8B-9D00-C44F5DC4234EQ48277880-4CB2CED7-DC30-467F-89D3-87D6D97F8458Q52647565-AC9FE8FA-7170-469E-ABDF-7F027A6D0FFF
P2860
Androgen deprivation therapy in advanced prostate cancer: is intermittent therapy the new standard of care?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Androgen deprivation therapy i ...... rapy the new standard of care?
@en
type
label
Androgen deprivation therapy i ...... rapy the new standard of care?
@en
prefLabel
Androgen deprivation therapy i ...... rapy the new standard of care?
@en
P2860
P356
P1433
P1476
Androgen deprivation therapy i ...... rapy the new standard of care?
@en
P2093
P2860
P304
P356
10.3747/CO.19.1298
P433
P50
P577
2012-12-01T00:00:00Z